Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines

J Am Coll Cardiol. 2015 Apr 7;65(13):1361-1368. doi: 10.1016/j.jacc.2015.01.043.

Abstract

Successful implementation of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines hinges on a clear understanding of the clinician-patient risk discussion (CPRD). This is a dialogue between the clinician and patient about potential for atherosclerotic cardiovascular disease risk reduction benefits, adverse effects, drug-drug interactions, and patient preferences. Designed especially for primary prevention patients, this process of shared decision making establishes the appropriateness of a statin for a specific patient. CPRD respects the autonomy of an individual striving to make an informed choice aligned with personal values and preferences. Dedicating sufficient time to high-quality CPRD offers an opportunity to strengthen clinician-patient relationships, patient engagement, and medication adherence. We review the guideline-recommended CPRD, the general concept of shared decision making and decision aids, the American College of Cardiology/American Heart Association Risk Estimator application as an implementation tool, and address potential barriers to implementation.

Keywords: cerebrovascular disease; coronary heart disease; lipid-lowering therapy; myocardial infarction; risk estimation; shared decision making.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • American Heart Association
  • Atherosclerosis / drug therapy
  • Atherosclerosis / prevention & control*
  • Decision Making
  • Female
  • Guidelines as Topic
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Male
  • Physician-Patient Relations*
  • Primary Prevention / methods*
  • Risk Assessment
  • Risk Factors
  • Risk Reduction Behavior
  • United States

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors